Complications of therapeutic gastroscopy/colonoscopy other than resection

Nabi, Zaheer

doi:10.1016/j.bpg.2016.10.010

Cited by 12 publications

(5 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complications of the injection therapy are usually associated with the effects of the drug injected (10). Among the most threatening complications are tissue necrosis, ulceration and perforation, as well as hypertension, and cardiac arrhythmia (13,16). Today, in addition to the injection therapy, which should not be used as monotherapy, there are few convincing data that would definitely give preference to specific methods of haemostasis.…”

Section: A B Cmentioning

confidence: 99%

Experimental Substantiation of Autoplasma Application as a Haemostatic Agent in Endoscopic Operations in the Digestive Tract

Бочкова

Gantsev

2020

Serbian Journal of Experimental and Clinical Research

View full text Add to dashboard Cite

Introduction. In endosurgery of the digestive tract, ‘cellular technologies’ are gaining popularity, including the use of blood components or blood cells with a haemostatic purpose. In this regard, the objective of the study is evaluation of the effectiveness of bleeding control and safety of resection of the hollow organs of the digestive tract in the experimental trauma models of the abdominal organs in laboratory animals.Materials and methods. The study was conducted in 20 mature male Chinchilla rabbits with the mean body mass of 2450 ± 210 g. All animals were divided into four experimental groups: the control group (without bleeding control); the group that received the infiltration of the wall of a hollow organ with saline; the group in which bleeding was controlled by argon plasma coagulation (APC), and the group wherein animals underwent haemostasis with autoplasma.Results. In the control group and the physiological saline group, no statistical difference was observed in the time of bleeding control. Autoplasma, due to preventive local administration, is more effective than APC and has a high haemostatic potential.Conclusion. Autoplasma has been found to be highly effective and safe for bleeding control in the gastrointestinal tract in the experimental model, which has paved the way for new possibilities for operations of various scales, including endoscopic operations.

show abstract

Section: A B Cmentioning

confidence: 99%

Experimental Substantiation of Autoplasma Application as a Haemostatic Agent in Endoscopic Operations in the Digestive Tract

Бочкова

Gantsev

2020

Serbian Journal of Experimental and Clinical Research

View full text Add to dashboard Cite

show abstract

“…Adverse events of injection therapy are usually related to the substance injected rather than to the needle itself 3 . Rare adverse events include tissue necrosis, ulceration, and perforation, and also hypertension and cardiac arrhythmia with epinephrine injection 120, 121. Serious adverse events of endoscopic thermal hemostasis include uncontrollable bleeding and perforation 122 .…”

Section: Safetymentioning

confidence: 99%

Devices for endoscopic hemostasis of nonvariceal GI bleeding (with videos)

et al. 2019

View full text Add to dashboard Cite

Background Endoscopic intervention is often the first line of therapy for GI nonvariceal bleeding. Although some of the devices and techniques used for this purpose have been well studied, others are relatively new, with few available outcomes data. Methods In this document, we review devices and techniques for endoscopic treatment of nonvariceal GI bleeding, the evidence regarding their efficacy and safety, and financial considerations for their use. Results Devices used for endoscopic hemostasis in the GI tract can be classified into injection devices (needles), thermal devices (multipolar/bipolar probes, hemostatic forceps, heater probe, argon plasma coagulation, radiofrequency ablation, and cryotherapy), mechanical devices (clips, suturing devices, banding devices, stents), and topical devices (hemostatic sprays). Conclusions Endoscopic evaluation and treatment remains a cornerstone in the management of nonvariceal upper- and lower-GI bleeding. A variety of devices is available for hemostasis of bleeding lesions in the GI tract. Other than injection therapy, which should not be used as monotherapy, there are few compelling data that strongly favor any one device over another. For endoscopists, the choice of a hemostatic device should depend on the type and location of the bleeding lesion, the availability of equipment and expertise, and the cost of the device.

show abstract

“…Low gastrointestinal bleeding (LGIB) accounts for 20-25% of all gastrointestinal (GI) bleeding episodes [1,2]. Although LGIB is relatively less common than upper GI bleeding, it remains a frequent cause of hospitalization, with a mortality rate of up to 20% [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…Indeed, hemoclips are not suitable for diffuse bleeding lesions and can cause mechanical mucosal damage by the device. Although thermocoagulation is suitable for large bleeding surfaces, endoscopists need to consider coagulation syndrome and delayed perforation [1,7].…”

Section: Introductionmentioning

confidence: 99%

Hemostatic efficacy and safety of the hemostatic powder UI-EWD in patients with lower gastrointestinal bleeding

et al. 2022

View full text Add to dashboard Cite

Background and aims Acute lower gastrointestinal bleeding (LGIB) is a common cause of emergency hospitalization and may require readmission for re-bleeding. Recently, a novel endoscopic hemostatic powder (UI-EWD/Nexpowder™, Nextbiomedical, Incheon, South Korea) was developed and applied for the control of LGIB. The aim of this study was to evaluate the hemostatic efficacy and long-term safety of UI-EWD in LGIB. Patients and methods We conducted a retrospective cohort study of LGIB at a single tertiary center in south Korea. One hundred and sixty-seven consecutive patients with LGIB who were initially successful in endoscopic hemostasis were included and divided into the conventional treatment group (n = 112) and the UI-EWD therapy group (n = 55; 38 patients with conventional treatment and 17 patients with UI-EWD alone). The success rate of hemostasis, adverse events related to UI-EWD, and re-bleeding rate were evaluated. Results The incidence of endoscopic hemostasis applied to the hepatic flexure (7.3% vs. 0%, p = 0.011) and larger than 4 cm (25.5% vs. 8.0%, p = 0.002) were significantly higher in the UI-EWD group than in the conventional therapy group. The cumulative rebleeding rate within 28 days in the UI-EWD group was 5.5% (3/55), which was significantly lower than that in the conventional treatment group (17.0% [19/112]; p = 0.039). No UI-EWD-related adverse events were recorded. Conclusion Based on our results, application of UI-EWD in LGIB showed promising results for the prevention of re-bleeding, especially in locations where it is difficult to approach or cases with more bleeding. There were no significant complications, such as perforation or embolism. In particular, UI-EWD should be considered first for anatomical or technical impediments to endoscopic access in LGIB.

show abstract

Complications of therapeutic gastroscopy/colonoscopy other than resection

Cited by 12 publications

References 81 publications

Experimental Substantiation of Autoplasma Application as a Haemostatic Agent in Endoscopic Operations in the Digestive Tract

Experimental Substantiation of Autoplasma Application as a Haemostatic Agent in Endoscopic Operations in the Digestive Tract

Devices for endoscopic hemostasis of nonvariceal GI bleeding (with videos)

Hemostatic efficacy and safety of the hemostatic powder UI-EWD in patients with lower gastrointestinal bleeding

Contact Info

Product

Resources

About